Factors influencing adherence to antiretroviral medication in Ilorin, Nigeria

Journal of the International Association of Physicians in AIDS Care

Volumn 9, Issue 3, 2010, Pages 191-195

  Salami, Alakija Kazeem ^a   Fadeyi, Abayomi ^a   James, Ogunmodede ^a   Desalu, Olufemi ^a  

^a UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

Adherence; HAART; HIV; Ilorin; PLWHA

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONSULTATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NIGERIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT;

ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NIGERIA; QUESTIONNAIRES; SEX FACTORS;

EID: 77953658606     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109710368722     Document Type: Article

References (32)

1. UNAIDS/WHO: AIDS epidemic update. 2007. "UNAIDS/ 07.27E/JC1322E." www.data.unaids.org/Pub/EPISlides/2007/2007-epiupdate-en. pdf. Accessed February 24, 2009.
2. Businessday. Access to ARVs crucial to checking HIV/AIDS scourge. http://www.businessdayonline.com/index.php?option=com-content&view= article&id=8172:access-to-arvs-crucial-tochecking-hivaids-scourge&catid= 126:health. Accessed February 24, 2009.
3. Virtual Hospital. 2008 National HIV Sero-Prevalence Sentinel Survey among the antenatal clinic attendees. http://www.virtualhospitalng.com/ 2008ANC%20Survey%20findings.htm. Accessed February 24, 2009.
4. Friedland G. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005; 17(1):10-22.
5. Tadios Y, Davey G. Antiretroviral treatment adherence and its correlates among people living with HIV/AIDS on highly active antiretroviral therapy in Addis Ababa, Ethiopia. EMJ. 2006; 44(3):237-244.
6. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349(9061): 1294.
7. Remien RVV, Raxach JC, Parker R, Berkman A, Hacker MA, Bastos FI. Assessing non-adherence to highly active antiretroviral therapy (HAART) in a context of universal access, in Rio de Janeiro, Brazil. Int Conf AIDS. 2002;14:abstract no. B10445. Available at www.gateway.nlm.nih.gov/ MeetingAbstracts/102252798.html. Accessed February 24, 2009.
8. Rabkin JG, Chesney MA. Treatment adherence to AIDS medications: The Achilles heel of the new therapeutics. In: Ostrow D, Kalichman S, eds. Psychosocial and Public Health Impacts of New HIV Therapies. Kluwer/Plenum; New York: Kluwer/Plenum; 1999:61-68.
9. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triplecombination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051-1058.
10. Amico K, Rivet J, Harman J, Johnson BT. Efficacy of antiretroviral therapy adherence interventions-a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3): 285-297.
11. Sabate E. WHO adherence meeting report. Geneva: World Health Organization; 2001. http://www.who.int/chp/knowledge/publications/ adherencerep.pdf. Accessed February 24, 2009.
12. Carter M. Adherence-Information Series for HIV-Positive People: HIV and Children. 2nd ed. London: NAM; 2005. http://aidsmap.com/en/docs/pdf/hivchildren. pdf. Accessed February 24, 2009.
13. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
14. Shaahu VN, Lawoyin TO, Sangowawa AO. Adherence to HAART: The role of health care workers in Makurdi, Nigeria. Afri J Med Med Sci. 2008;37(1):29-36.
15. Uzochukwu BSC, Onwujekwe OE, Onoka AC, Okoli C, Uguru NP, Chukwuogo OI. Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan. 2009;24(3):189-196.
16. Alemayehu A, Kifle W, Sofonias G, Belaineh G, Kebede D. Predictors of adherence to antiretroviral therapy among HIV-infected persons: A prospective study in Southwest Ethiopia. BMC Public Health. 2008;8:265. http://www. biomedcentral.com/ 1471-2458-8-265. Accessed February 24, 2009.
17. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA. 2006;296(6):679-690.
18. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: A systematic review of developed and developing nation patient reported barriers and facilitators. PLoS Med. 2006;3(11):e438. http://www.plosmedicine.org/ article/info:doi/ 10.1371/journal.pmed.0030438. Accessed February 24, 2009.
19. Bonolo PF, César CC, Acúrcio FA, et al. Non-adherence among patients initiating antiretroviral therapy: A challenge for health professionals in Brazil. AIDS. 2005;19(suppl 4):S5-S13.
20. Molassiotis A, Nahas-Lopez V, Chung WY, Lam SW, Li CK, Lau TF. Factors associated with adherence to antiretroviral medication in HIV-infected patients. Int J STD AIDS. 2002; 13(5):301-310.
21. Mannheimer S, Matts J, Telzak E, et al., for the Terry Beirn Community Programs for Clinical Research on AIDS. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2004;17(1):10-22.
22. Wagner G, Miller LG. Is the influence of social desirability on patients' self-reported adherence overrated? J Acquir Immune Defic Syndr. 2004;35(2):203-204.
23. Fischl M, Ribaudo H, Collier A, et al. A randomized trial comparing 24-drug antiretroviral regimens with a 3-drug regimen in advanced HIV disease. Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, WA. http://gateway.nlm.nih.gov/MeetingAbstracts/ ma?f=102263665.html. Accessed February 24, 2009.
24. Fletcher CV, Testa MA, Haubrich R, et al. Relationships among four measures of medication adherence and virologic response in ACTG 359 (abstract 577). Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, MA. http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f= 102261199. html. Accessed February 24, 2009.
25. Nieuwkerk PT, Sprangers MA, Burger DM, et al., for the ATHENA project. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161(16):1962-1968.
26. Arnsten J, Demas P, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417-1423.
27. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population. AIDS. 2000;14(4): 357-366.
28. Nilsson Schönnesson L, Diamond PM, Ross MW, Williams M, Bratt G. Baseline predictors of three types of antiretroviral therapy (ART) adherence: A 2-year follow-up. AIDS Care. 2006; 18(3):246-253.
29. Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy. AIDS Care. 2006;18(7):853-861.
30. Fedders DO. Drug use in the elderly: Issues of noncompliance. Drug Intell Clin Pharm. 1984;18(2):158-162.
31. Singh N, Squier C, Hayes P, et al. Determinants of compliance in patients with HIV: Prospective assessment with implications for enhancing compliance. Paper presented at: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994; Orlando [abstract I170]. http://gateway.nlm.nih.gov/ MeetingAbstracts/ma?f=102213792.html. Accessed February 24, 2009.
32. Sorensen SJ, Klinge HA, Mravca-Wilkey VL, Elzey J, Fife KH. Gender-related factors influencing medication and clinic visit adherence in HIV/AIDS patients. Int Conf AIDS. 2002;14: Abstract no. WePeB5856. http://gateway.nlm.nih. gov/MeetingAbstracts/ma?f=102254422.html. Accessed February 24, 2009.